FDX104 (4% Doxycycline)
FDX104-1
Phase 2 small_molecule completed
Quick answer
FDX104 (4% Doxycycline) for Rash Due to Epidermal Growth Factor Receptor Inhibitors is a Phase 2 program (small_molecule) at VYNE Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- VYNE Therapeutics
- Indication
- Rash Due to Epidermal Growth Factor Receptor Inhibitors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed